Asciminib, also known as ABL001, is a potent allosteric inhibitor of BCR-ABL. ABL001 prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Cell proliferation studies demonstrate that ABL001 selectively inhibited the growth of CML and Ph+ ALL cells with potencies ranging from 1-10nM range. ABL001 was tested for activity against clinically observed mutations and found to be active in the low nM range. In the KCL-22 mouse xenograft model, ABL001 displayed potent anti-tumor activity with complete tumor regression observed and a clear dose-dependent correlation with pSTAT5 inhibition.

 

Brand: BCM

 

Boiling Point: 631.7±55.0 °C at 760 mmHg

 

Flashing Point: 335.8±31.5 °C

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

InChi Key: VOVZXURTCKPRDQ-CQSZACIVSA-N

 

Attribute
[CAS No.]	1492952-76-7
[Formula]	C20H18ClF2N5O3
[Molecular]	449.843
[Chem Name]	(R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-3-yl)nicotinamide
[Synonym]	Asciminib; ABL001; ABL-001
[Storage]	Inert atmosphere. Store in freezer, under -20°C
[MDL No.]	MFCD31560488
[Form]	Solid powder

Goods Tag